Omada Health (NASDAQ:OMDA) Price Target Raised to $28.00

Posted by Stanley Muller on Jul 24th, 2026

Omada Health (NASDAQ:OMDA – Free Report) had its price target raised by Canaccord Genuity Group from $24.00 to $28.00 in a research note published on Tuesday morning, MarketBeat reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other research firms have also commented on OMDA. Morgan Stanley restated an “overweight” rating and issued a $30.00 price objective on shares of Omada Health in a research note on Monday, June 22nd. Barclays raised their price target on Omada Health from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Wells Fargo & Company boosted their price target on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. BTIG Research assumed coverage on Omada Health in a research note on Friday, July 17th. They set a “buy” rating and a $30.00 price objective for the company. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Omada Health in a research report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Omada Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.33.

Get Our Latest Report on Omada Health

Omada Health Stock Performance

Omada Health stock opened at $21.20 on Tuesday. The company has a market capitalization of $1.26 billion and a P/E ratio of -78.52. Omada Health has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The stock has a 50-day simple moving average of $19.56 and a 200-day simple moving average of $15.86.

Omada Health (NASDAQ:OMDA – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%.The firm had revenue of $78.05 million for the quarter. As a group, analysts forecast that Omada Health will post -0.01 earnings per share for the current year.

Insider Activity at Omada Health

In other Omada Health news, CFO Steven L. Cook sold 12,337 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $23.09, for a total transaction of $284,861.33. Following the transaction, the chief financial officer directly owned 187,209 shares in the company, valued at approximately $4,322,655.81. This represents a 6.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Sean P. Duffy sold 25,886 shares of Omada Health stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $22.68, for a total transaction of $587,094.48. Following the sale, the chief executive officer owned 411,861 shares of the company’s stock, valued at approximately $9,341,007.48. The trade was a 5.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 193,462 shares of company stock worth $3,927,425 over the last 90 days. Company insiders own 6.38% of the company’s stock.

Hedge Funds Weigh In On Omada Health

Several hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in Omada Health by 319.3% during the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock worth $66,000 after purchasing an additional 2,283 shares during the last quarter. Bank of America Corp DE grew its holdings in Omada Health by 51.5% in the first quarter. Bank of America Corp DE now owns 161,099 shares of the company’s stock valued at $2,025,000 after purchasing an additional 54,792 shares during the last quarter. Stoic Point Capital Management LLC purchased a new position in shares of Omada Health in the first quarter valued at $1,830,000. Quantinno Capital Management LP increased its position in shares of Omada Health by 464.1% in the first quarter. Quantinno Capital Management LP now owns 58,723 shares of the company’s stock valued at $738,000 after buying an additional 48,313 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Omada Health during the 1st quarter worth $194,000.

About Omada Health

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.